X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EGL-001, a CTLA-4 targeted IL-2 dominant negative mutein, immunocytokine that selectively binds to T regulatory cells and inhibits Treg IL-2 signaling. It is being developed for treatment of advanced solid tumors.
Lead Product(s): EGL-001
Therapeutic Area: Oncology Product Name: EGL-001
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2024
Details:
Egle plans a strategic investment in a First-In-Class technology platform based on innovative research with novel T regulatory cell therapy modulations and potential in the oncology and auto-immunity fields.
Lead Product(s): T-regulatory Cells Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: LSP
Deal Size: $46.4 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 22, 2021
Details:
In the course of the strategic research alliance that was announced in June 2020, Egle will validate novel tumor-infiltrating regulatory T-cell (Treg) targets against which Takeda will develop potential therapies.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 26, 2020
Details:
Under the terms of the agreement, Egle Therapeutics will lead target validation efforts on a subset targets Egle has identified and Takeda will be responsible for the development, manufacturing, and commercialization of resulting therapies.
Lead Product(s): Tumor-infiltrating Treg
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 11, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
